Progyny, Inc. (NASDAQ:PGNY) Stock Has Consensus Target Price of $34.36

Shares of Progyny, Inc. (NASDAQ:PGNY) have been given a consensus rating of “Moderate Buy” by the thirteen analysts that are covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $34.36.

Several analysts recently issued reports on the company. Wall Street Zen upgraded Progyny from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 19th. Zacks Research raised Progyny from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 8th. Truist Financial boosted their price target on Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Jefferies Financial Group set a $33.00 price target on Progyny in a research note on Tuesday, September 8th. Finally, Weiss Ratings upgraded Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th.

Insider Activity

In other news, EVP Allison Swartz sold 3,903 shares of the business’s stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $26.10, for a total value of $101,868.30. Following the transaction, the executive vice president owned 75,816 shares of the company’s stock, valued at approximately $1,978,797.60. The trade was a 4.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Melissa Cummings sold 1,879 shares of the business’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $28.00, for a total transaction of $52,612.00. Following the completion of the transaction, the chief operating officer directly owned 66,496 shares in the company, valued at $1,861,888. This trade represents a 2.75% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 17,282 shares of company stock worth $475,790 over the last quarter. Insiders own 9.90% of the company’s stock.

Institutional Trading of Progyny

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Hsbc Holdings PLC purchased a new stake in shares of Progyny during the 2nd quarter worth approximately $760,000. AWM Investment Company Inc. bought a new position in shares of Progyny during the 2nd quarter valued at approximately $6,343,000. Bank of America Corp DE bought a new position in shares of Progyny during the 2nd quarter valued at approximately $17,264,000. Corient Private Wealth LP purchased a new position in shares of Progyny in the second quarter valued at $3,488,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Progyny in the second quarter valued at $1,705,000. 94.93% of the stock is currently owned by institutional investors.

Progyny Stock Performance

Shares of Progyny stock opened at $28.58 on Friday. The company has a market capitalization of $2.19 billion, a P/E ratio of 31.07, a P/E/G ratio of 1.92 and a beta of 1.02. The company has a fifty day moving average of $26.44 and a 200 day moving average of $25.67. Progyny has a fifty-two week low of $16.10 and a fifty-two week high of $33.06.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The business had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. During the same period last year, the firm earned $0.19 earnings per share. The business’s quarterly revenue was up 5.3% on a year-over-year basis. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Analysts forecast that Progyny will post 1.25 EPS for the current year.

About Progyny

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.